MedTrace Logo

Research Evaluating a PDE5 Inhibitor for Erectile Dysfunction

NCT01698684 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 440

Last updated 2014-10-27

Study results available
· View outcomes & findings →

Summary

The objectives of this study are to examine the therapeutic effects of two doses of avanafil after dosing in men with erectile dysfunction

Conditions

Interventions

DRUG

Placebo

One dose 15 minutes before attempting intercourse

DRUG

Avanafil 100 mg

One dose 15 minutes before attempting intercourse

DRUG

Avanafil 200 mg

One dose 15 minutes before attempting intercourse

Sponsors & Collaborators

  • VIVUS LLC

    lead INDUSTRY

Principal Investigators

  • Chuck Bowden, M.D. · VIVUS LLC

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-09-30
Primary Completion
2013-04-30
Completion
2013-04-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01698684 on ClinicalTrials.gov